Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Purchased by Augustine Asset Management Inc.

Augustine Asset Management Inc. raised its holdings in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 392.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 249,744 shares of the company's stock after purchasing an additional 199,044 shares during the period. Dr. Reddy's Laboratories accounts for approximately 1.0% of Augustine Asset Management Inc.'s investment portfolio, making the stock its 18th biggest holding. Augustine Asset Management Inc.'s holdings in Dr. Reddy's Laboratories were worth $3,943,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in RDY. Farther Finance Advisors LLC boosted its stake in Dr. Reddy's Laboratories by 43.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 454 shares of the company's stock worth $36,000 after purchasing an additional 137 shares in the last quarter. Van ECK Associates Corp raised its holdings in shares of Dr. Reddy's Laboratories by 64.3% in the third quarter. Van ECK Associates Corp now owns 823 shares of the company's stock worth $64,000 after buying an additional 322 shares during the last quarter. Lifestyle Asset Management Inc. lifted its stake in shares of Dr. Reddy's Laboratories by 3.2% during the third quarter. Lifestyle Asset Management Inc. now owns 13,689 shares of the company's stock worth $1,088,000 after buying an additional 422 shares during the period. Natixis Advisors LLC grew its holdings in shares of Dr. Reddy's Laboratories by 7.2% during the third quarter. Natixis Advisors LLC now owns 10,937 shares of the company's stock valued at $869,000 after buying an additional 735 shares during the last quarter. Finally, Venturi Wealth Management LLC acquired a new position in shares of Dr. Reddy's Laboratories in the 3rd quarter valued at $60,000. Hedge funds and other institutional investors own 3.85% of the company's stock.

Remove Ads

Dr. Reddy's Laboratories Stock Performance

Shares of NYSE:RDY traded down $0.40 during trading on Friday, hitting $13.60. 1,802,113 shares of the stock traded hands, compared to its average volume of 1,994,837. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. The company has a fifty day moving average price of $14.73 and a two-hundred day moving average price of $15.29. Dr. Reddy's Laboratories Limited has a 52-week low of $13.36 and a 52-week high of $16.89. The company has a market cap of $11.35 billion, a price-to-earnings ratio of 21.65 and a beta of 0.50.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. As a group, equities analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on RDY shares. Nomura cut Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research report on Thursday, December 19th. StockNews.com downgraded Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a report on Friday, December 6th. Finally, Barclays cut their price target on shares of Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating on the stock in a report on Wednesday, November 6th.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.